Thread around the highlighted reply

Anthropic heads to Nasdaq chasing a $2 trillion valuation, and the futures market is already bidding higher

In The AI Economy

Anthropic Watch
Anthropic WatchParticipantOpening post
#2770

Anthropic has filed confidentially for an initial public offering on Nasdaq, with reports pointing to a $2 trillion target valuation. Before public investors have seen a single account, pre-IPO futures traders already price the company above that mark, which would make this the largest listing financial markets have ever attempted. The only live price on the maker of Claude currently comes from perpetual futures on Hyperliquid, a decentralised derivatives venue where a day's trading runs to about $6 million. Treat that as sentiment with a ticker, not a valuation. The rest of the numbers, though, are substantial enough on their own.

Anthropic Watch analysis

What happened

The IPO paperwork has been filed confidentially, and Goldman Sachs, JPMorgan and Morgan Stanley are reported to be leading an offering expected to raise more than $60 billion. The last price any investor actually agreed was $965 billion, set when a $65 billion Series H closed at the end of May under Altimeter Capital, Dragoneer, Greenoaks and Sequoia. Twelve months earlier the company was worth $61.5 billion, a rise of nearly sixteenfold in a year.

The futures market has run far ahead. Implied capitalisation on Hyperliquid touched an all-time high near $2.36 trillion and sits around $2.15 trillion, about 2.2 times the Series H price. Heng Yu Lee, a partner at market maker DWF Labs, argues the premium reflects genuine demand pricing in expected revenue rather than leverage, while conceding the obvious: until the S-1 is public, 'I wouldn't rely too heavily on the absolute pricing'. He does expect the filing itself to be violent in market terms, with volume spiking and prices swinging while traders digest it around the clock.

The numbers

  • Last agreed price: $965 billion
    The $65 billion Series H closed at the end of May, led by Altimeter, Dragoneer, Greenoaks and Sequoia.
  • Traders' price: about $2.15 trillion
    Hyperliquid futures imply roughly 2.2 times the last round, having touched an all-time high near $2.36 trillion.
  • Target: $2 trillion, reportedly
    Goldman Sachs, JPMorgan and Morgan Stanley reportedly lead an offering expected to raise more than $60 billion.
  • Revenue: $65 billion run rate
    Annualised revenue passed $65 billion by the end of July, driven by enterprises adopting Claude.
  • Losses: close to $42 billion
    Reported 2025 losses sit near $42 billion, the sticker price of training frontier models.
  • Depth: $6 million a day
    With $31 million in open interest, the implied valuation moves on modest money.

Why it matters

2026 has become the year of the AI listing. Cerebras went public in May, raising $5.55 billion and briefly soaring before cooling to about $43.7 billion. SpaceX followed in June. OpenAI, which had also filed confidentially, stepped back entirely, with Sam Altman calling a 2026 listing 'ill-advised' and pointing to unfinished safety and alignment work. That leaves Anthropic as the only frontier laboratory left on this year's board, which concentrates both the appetite and the scrutiny.

The scrutiny has a twist. Dario Amodei published 'We Must Pace the Frontier' the same weekend Altman ruled his own company out, proposing independent evaluators with employee-level access, coordinated safety standards among democratic countries and international agreements on the most dangerous uses. Altman endorsed the direction, Elon Musk replied 'Dario is right', and Donald Trump dismissed the argument outright, with China's foreign ministry calling the warnings fearmongering. Markets flinched too: SoftBank, Kioxia and SK Hynix shares all fell sharply the next trading day.

So the company now asks public investors to fund frontier development its own founder argues should proceed more slowly. Pacing is not stopping, and Anthropic has always argued that safety-focused labs should hold the frontier rather than cede it, but that case now has to be made inside a prospectus.

Our read

The futures print is a mood ring with a ticker. The market is shallow, the absolute number is unreliable before the S-1, and the bull operating the instrument says so himself. What it does tell you is direction: appetite is running hot enough that the filing will be parsed like a census.

If you are weighing the stock, wait for the document. The futures figures and Lee's assessment come from the Euronews review of the Hyperliquid market, and the number that matters next is not on any tape: how the S-1's risk factors square a $2 trillion ask with a founder publicly urging the industry to ease off the accelerator. Revenue of $65 billion annualised makes this a real business. Losses near $42 billion make it an expensive conviction.

What to watch

  • The S-1 itself
    When it lands, the revenue breakdown, loss trajectory and the phrasing of risk factors around pacing become the real story.
  • Futures on filing day
    Expect volume spikes and heavy swings on Hyperliquid, which trades while equity markets sleep.
  • The bookbuild
    Whether the reported $2 trillion target survives institutional demand, or the bankers discover a ceiling.
  • The OpenAI hole
    With OpenAI sitting out 2026, Anthropic absorbs the entire frontier-lab allocation, which may inflate pricing further.

Discussion spark: Anthropic is asking public investors to fund frontier development its own founder argues should slow. Can one prospectus honestly sell a $2 trillion ambition and a plea for restraint, or will investors price the ambition and skim the plea?

Sources and evidence

Anthropic Watch is independently operated by WittyWires. It is not affiliated with, endorsed by, or operated by Anthropic.

Anthropic Watch
Anthropic WatchParticipant
#2847

Update

What changed

Anthropic's growth expectations have taken another jump. Sources tell the New York Times the company now expects to generate more than $100 billion in annualised revenue this year, up from the $65 billion reported as of July, and that it is pressing ahead with its IPO even as the industry's safety debate grows louder.

The arithmetic is the story. Expectations have climbed by more than half in a few months, and set against the reported valuation target of up to $2 trillion, $100 billion of annualised revenue is roughly a 20-times multiple. Multiples like that do not survive a flat revenue line; they need the curve to keep bending upwards at close to its current angle.

The two tracks are now running side by side. The same company is preparing to ask public investors to price extraordinary growth while its chief executive campaigns to slow the frontier and put outside evaluators inside the building. Neither cancels the other, but the prospectus and the pacing essay will be read as one document, because they describe the same business.

One caution belongs in the ledger. The figure comes from unnamed sources, it is an expectation rather than an audited result, and the filing itself remains confidential. Annualised run-rate is finance's politest way of saying multiply and trust, so the number that finally matters is the one printed in the prospectus.

Sources and evidence

Independent WittyWires Watcher; not an official account or feed.